Search

Royalty Pharma PLC (Class A)

Uždarymo kaina

SektoriusSveikatos priežiūra

63.87 1.27

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

62.45

Max

63.92

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-589M

-295M

Pardavimai

44M

674M

P/E

Sektoriaus vid.

32.665

56.659

Pelnas, tenkantis vienai akcijai

1.32

Dividendų pajamingumas

1.5

Pelno marža

-43.713

Darbuotojai

100

EBITDA

-387M

176M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+5.38% upside

Dividendai

By Acuity

Dividendų pajamingumas

Sektoriaus vid.

1.50%

2.18%

Kitas uždarbis

2026-11-04

Kitas dividendų mokėjimo data

2026-09-10

Kita Ex Dividend data

2026-11-13

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

2.6B

35B

Ankstesnė atidarymo kaina

62.6

Ankstesnė uždarymo kaina

63.87

Naujienos nuotaikos

By Acuity

81%

19%

315 / 340 reitingas Healthcare

Royalty Pharma PLC (Class A) Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-02 23:06; UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting a slight decline since Wednesday's close, despite earlier recovery attempts.

2026-09-01 20:09; UTC

Royalty Pharma PLC is rising as strength in the pharmaceuticals sub-sector boosts shares. The stock remains near its one-month high despite a recent pullback.

2026-08-31 23:16; UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting positive market sentiment. The stock remains near the upper end of its one-month trading range.

2026-08-28 20:07; UTC

Royalty Pharma PLC shares are lower today amid broader market declines and rising U.S. Treasury yields, reflecting ongoing volatility in the pharmaceuticals sector.

2026-08-27 23:11; UTC

Royalty Pharma PLC shares are higher in after-market trading, supported by a favorable performance backdrop and positioning above the 20-day moving average.

2026-08-26 23:16; UTC

Royalty Pharma PLC shares are higher in after-market trading, currently above their 20-day moving average and near the upper end of their one-month range.

2026-08-25 20:07; UTC

Royalty Pharma PLC shares are higher today, continuing an upward trend since Monday. Lower Treasury yields are supporting investor sentiment in the market.

2026-08-24 20:06; UTC

Royalty Pharma PLC shares are near unchanged as market sentiment is influenced by rising oil prices and geopolitical tensions from new U.S. sanctions against Iran.

2026-08-21 19:26; UTC

Royalty Pharma PLC shares are higher, reflecting a broader rebound in U.S. stocks amid economic uncertainties and rising inflation. The asset remains above its 20-day moving average.

2026-08-20 23:11; UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline from earlier in the session amid mixed broader market sentiment.

2026-08-19 20:02; UTC

Royalty Pharma PLC shares are higher today, driven by strong investor interest in pharmaceuticals and unusually high market volume during regular trading hours.

2026-08-18 23:21; UTC

Royalty Pharma PLC shares are higher in after-market trading, continuing an upward trend from previous sessions. No specific news was identified for this movement.

2026-08-17 19:36; UTC

Royalty Pharma PLC shares are trading higher during Monday's session, recovering from an earlier dip and remaining above the 20-day moving average.

2026-08-15 00:01; UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a routine decline since Friday's close amid mixed global equity market performance.

2026-08-14 19:46; UTC

Event
Social Media

Royalty Pharma PLC declared a $0.235 per share dividend today, with shares advancing since Thursday's close and near the upper end of their one-month range.

2026-08-13 20:02; UTC

Social Media

Royalty Pharma PLC shares are lower amid a $100 million royalty agreement with Zealand Pharma for rusfertide rights, reflecting unusual trading activity.

2026-08-12 20:01; UTC

Royalty Pharma PLC shares are higher today, supported by a broader market trend of gains since Tuesday. The stock is seeing unusually high trading volume.

2026-08-11 19:56; UTC

Royalty Pharma PLC shares are trading higher, reaching a session high earlier today. No specific news was identified to explain the price movement.

2026-08-10 23:16; UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting notable strength and unusual activity since Monday's close, with no specific news identified.

2026-08-07 23:41; UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting notable gains since Friday's close amid a shift toward a dovish monetary policy outlook.

2026-08-06 23:01; UTC

Royalty Pharma PLC shares are higher in after-market trading, moving above Thursday's close, despite remaining below the 20-day moving average.

2026-08-05 19:31; UTC

News

Royalty Pharma PLC raised its full-year guidance for Portfolio Receipts to $3.4 billion to $3.5 billion, contributing to a higher trading session.

2026-08-04 19:26; UTC

Royalty Pharma PLC shares are higher today, rebounding after earlier pulling back from a session high. The stock has fluctuated within a routine range.

2026-08-03 23:46; UTC

Royalty Pharma PLC shares are near unchanged in after-market trading, reflecting minimal movement since Monday's close and remaining below the 20-day moving average.

2026-08-01 00:03; UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline over the past four sessions. No specific news was identified to explain the move.

2026-07-31 23:01; UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting broader market trends despite some gains in mega-cap stocks. The stock remains below its 20-day moving average.

2026-07-30 22:01; UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting strong demand and trading above its 20-day moving average. No specific news was identified.

2026-07-29 19:27; UTC

Royalty Pharma PLC shares are lower today, reflecting a pullback since Tuesday's close amid rising oil prices and inflation concerns.

2026-07-28 23:46; UTC

Royalty Pharma PLC shares are lower in after-market trading, reflecting broader market declines amid concerns over technology sector dynamics.

2026-07-27 16:46; UTC

Royalty Pharma PLC shares are advancing during Monday's session. Broader market gains are supported by a notable decline in oil prices amid easing geopolitical tensions.

Akcijų palyginimas

Kainos pokytis

Royalty Pharma PLC (Class A) Prognozė

Kainos tikslas

By TipRanks

5.38% į viršų

12 mėnesių prognozė

Vidutinis 65.67 USD  5.38%

Aukščiausias 70 USD

Žemiausias 62 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Royalty Pharma PLC (Class A) kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

7

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

315 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
help-icon Live chat